U.S. Department of Veterans Affairs Begins National Rollout of WCG’s IRBNet
WCG announced that the U.S. Department of Veterans Affairs’ (VA) Office of Research and Development is successfully implementing WCG’s IRBNet electronic submission and review system for more than 100 VA medical centers (VAMCs) that have research programs.
In 2019, the VA selected IRBNet over other available solutions as the best solution to meet its complex research and compliance needs on an enterprise scale and to standardize processes among all sites. IRBNet provides technology-supported workflow, communication and documentation capabilities, assisting IRB compliance with ethical and regulatory standards for the inclusion of appropriate human subject protections, and the oversight of study conduct as mandated by federal guidelines.
“We are delighted that all the VA sites will now be using IRBNet. We specifically designed the platform to facilitate IRB compliance and increase productivity,” said Jeremy Katz, President, WCG IRBNet. “By reducing VA IRB staff’s administrative burden, IRBNet allows them to devote more time to other high priority activities, such as training and protocol development.”
For more information, click here.
Moderna’s mRNA-1010 Flu Vaccine Meets Efficacy Goals in Phase III Trial of Adults 50+
July 10th 2025In the P304 Phase III study, Moderna’s mRNA-1010 demonstrated a 26.6% relative efficacy over a standard-dose flu vaccine in adults aged 50+, showing consistent protection across strains and age groups.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
QWINT-1 Trial: Once-Weekly Efsitora Matches Daily Glargine in Type 2 Diabetes Management
July 10th 2025Results from the Phase III QWINT-1 trial show that Eli Lilly’s once-weekly insulin efsitora is noninferior to once-daily glargine in reducing HbA1c among insulin-naïve adults with type 2 diabetes, offering a simplified fixed-dose regimen with fewer hypoglycemic events and less treatment burden.
